Lilly Partners with Samsung Biologics for Gateway Labs in South Korea's Biotech Expansion
- Eli Lilly partners with Samsung Biologics to create Gateway Labs in Incheon, enhancing South Korea's biotech ecosystem.
- The facility will support up to 30 biotech firms and aims for completion in July 2027.
- Lilly's initiative fosters collaboration and scientific engagement, boosting Korea's position in life sciences innovation.
Strategic Expansion in South Korea: Lilly's Gateway Labs Initiative
Eli Lilly and Company (Lilly) forges a pivotal partnership with Samsung Biologics to establish a new Lilly Gateway Labs (LGL) facility in Incheon, South Korea. This collaboration aims to enhance the biotech ecosystem in the region significantly. The facility, set within Samsung's Bio Campus II, will span five stories and cover 125,000 square feet, dedicated to fostering innovation for early-stage biotech firms. With an expected completion date in July 2027, the Gateway Labs will provide a robust infrastructure to support up to 30 biotech companies, enhancing collaboration across the biotechnology landscape.
The establishment of the Lilly Gateway Labs facility is part of a broader initiative to solidify South Korea's position as a burgeoning hub for life sciences innovation. Samsung Biologics takes charge of managing the facility, while Lilly Gateway Labs will focus on fostering tailored scientific engagement and collaboration among local and international startups. This venture aspires to connect emerging companies with global industry experts, driving the translation of scientific advancements into practical applications vital for the growth of the national bio-industry. As demonstrated by the success of previous Lilly Gateway Labs, opened since 2019, the network has collectively raised over $3 billion and advanced more than 50 therapeutic programs, underscoring the potential impact of this new facility.
Julie Gilmore, Ph.D., vice president and global head of Lilly Gateway Labs, emphasizes that this expansion represents a significant step in establishing Korea as a dynamic center for life sciences. The collaboration reflects both organizations' commitment to advancing scientific expertise and economic development within the biotechnology sector in Korea. By providing essential resources and facilities for startups, Lilly and Samsung Biologics not only nurture nascent companies but also contribute to the overall growth and sustainability of Korea’s biotechnology industry.
In addition to this strategic endeavor, the partnership between Lilly and Samsung Biologics signals a broader trend of increased investment in biotech innovation globally. With emerging markets racing to develop their biotechnology sectors, regions like South Korea are poised to attract attention from various stakeholders in the life sciences community.
Related Cashu News

Bristol-Myers Squibb's Reclassification Enhances Growth Potential in Defensive Investment Strategy
Bristol-Myers Squibb Company (Ticker: BMY) undergoes a key reclassification across the Russell indexes, marking a transformative moment for the company. Moving to the Russell 1000 Defensive and Russel…

Vertex Pharmaceuticals' Casgevy Gains FDA Approval for Expanded Sickle Cell Disease Treatment Options
Vertex Pharmaceuticals (Ticker: VRTX) receives a significant boost in its ongoing battle against sickle cell disease with the recent FDA approval of an expanded label for its gene therapy product, Cas…

Gilead Sciences Gains FDA Approval for Trodelvy in First-Line Triple-Negative Breast Cancer Treatment
Gilead Sciences (Ticker: GILD) makes significant strides in oncology therapy with the recent approval of its drug Trodelvy for patients with unresectable or metastatic triple-negative breast cancer. T…

Merck Advances HIV Treatment and Faces Regulatory Scrutiny Amidst Market Success
Merck & Co. (Ticker: MRK) has recently made significant strides in the pharmaceutical landscape, particularly with its advancements in HIV treatment. The company's innovative drug, IDVYNSO, has receiv…

